Original paper
Association between immune-related adverse events (irAEs) and atezolizumab efficacy in advanced NSCLC: analyses from the Ph III study OAK
Abstract
OAK, the first randomized Ph III study of atezolizumab (atezo; anti-PD-L1), demonstrated a superior survival benefit with atezo vs. docetaxel (doc) in NSCLC patients (pts) who had failed prior platinum therapy (HR 0.73; 95% CI: 0.62, 0.87). This analysis evaluates the benefit of atezo in pts with and without irAEs from the primary efficacy population (n = 850) of OAK. Safety data are reported...
Paper Details
Title
Association between immune-related adverse events (irAEs) and atezolizumab efficacy in advanced NSCLC: analyses from the Ph III study OAK
Published Date
Feb 21, 2018
Journal
Volume
72
Issue
S 01
Pages
S56 - S56
Citation AnalysisPro
You’ll need to upgrade your plan to Pro
Looking to understand the true influence of a researcher’s work across journals & affiliations?
- Scinapse’s Top 10 Citation Journals & Affiliations graph reveals the quality and authenticity of citations received by a paper.
- Discover whether citations have been inflated due to self-citations, or if citations include institutional bias.
Notes
History